Lunning, MA, Wang, H, Hu, Z-H, et al. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024; 99(5): 880–889. doi:10.1002/ajh.27283

In Table 1, a typographical error was made in which the patient numbers and percentages for “Male” and “Female” have been reversed for each treatment arm. The number and proportion of female patients should be “412 (36)” in the axi-cel arm and “172 (37)” in the CIT arm. For male patients, the number and proportions should be “734 (64)” for the axi-cel arm and “297 (63)” for the CIT arm.

We apologize for this error.

伦宁，马，王，H，胡，ZH，等。对于老年患者和/或经 2 线或以上治疗后患有复发性或难治性大 B 细胞淋巴瘤且 ECOG 表现状态不佳的患者，axicabtagene ciloleucel 与化学免疫疗法相比的益处。Am J Hematol。 2024；99（5）：880 – 889。 doi：10.1002/ajh.27283

在表 1 中，存在印刷错误，其中每个治疗组的“男性”和“女性”的患者人数和百分比已颠倒。 axi-cel 组中女性患者的数量和比例应为“412 (36)”，CIT 组中女性患者的数量和比例应为“172 (37)”。对于男性患者，axi-cel 组的数量和比例应为“734 (64)”，CIT 组的数量和比例应为“297 (63)”。

对于这个错误，我们深表歉意。